Literature DB >> 35622273

N-myc Downstream-Regulated Gene 2 (Ndrg2): A Critical Mediator of Estrogen-Induced Neuroprotection Against Cerebral Ischemic Injury.

Jin Wang1, Min Liu2, Wugang Hou1, Min Hou3, Lixia Zhang4, Miao Sun3, Siyuan Liu5, Huikai Yang3, Hang Guo6, Xiaoying Zhang3, Fei Xie7, Yanhong Liu8, Yulong Ma9.   

Abstract

Growing evidence indicates that estrogen plays a pivotal role in neuroprotection against cerebral ischemia, but the molecular mechanism of this protection is still elusive. N-myc downstream-regulated gene 2 (Ndrg2), an estrogen-targeted gene, has been shown to exert neuroprotective effects against cerebral ischemia in male mice. However, the role of Ndrg2 in the neuroprotective effect of estrogen remains unknown. In this study, we first detected NDRG2 expression levels in the cortex and striatum in both female and male mice with western blot analyses. We then detected cerebral ischemic injury by constructing middle cerebral artery occlusion and reperfusion (MCAO-R) models in Ndrg2 knockout or conditional knockdown female mice. We further implemented estrogen, ERα, or ERβ agonist replacement in the ovariectomized (OVX) Ndrg2 knockout or conditional knockdown female mice, then tested for NDRG2 expression, glial fibrillary acidic protein (GFAP) expression, and extent of cerebral ischemic injury. We found that NDRG2 expression was significantly higher in female than in male mice in both the cortex and striatum. Ndrg2 knockouts and conditional knockdowns showed significantly aggravated cerebral ischemic injury in female mice. Estrogen and ERβ replacement treatment (DPN) led to NDRG2 upregulation in both the cortex and striatum of OVX mice. Estrogen and DPN also led to GFAP upregulation in OVX mice. However, the effect of estrogen and DPN in activating astrocytes was lost in Ndrg2 knockout OVX mice and primary cultured astrocytes, but partially retained in conditional knockdown OVX mice. Most importantly, we found that the neuroprotective effects of E2 and DPN against cerebral ischemic injury were lost in Ndrg2 knockout OVX mice but partially retained in conditional knockdown OVX mice. These findings demonstrate that estrogen alleviated cerebral ischemic injury via ERβ upregulation of Ndrg2, which could activate astrocytes, indicating that Ndrg2 is a critical mediator of E2-induced neuroprotection against cerebral ischemic injury.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Astrocyte; Cerebral ischemic injury; ERβ; Estrogen; Ndrg2; Neuroprotection

Mesh:

Substances:

Year:  2022        PMID: 35622273     DOI: 10.1007/s12035-022-02877-5

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  26 in total

1.  Factors contributing to sex differences in functional outcomes and participation after stroke.

Authors:  Hoang T Phan; Christopher L Blizzard; Mathew J Reeves; Amanda G Thrift; Dominique A Cadilhac; Jonathan Sturm; Emma Heeley; Petr Otahal; Konstantinos Vemmos; Craig Anderson; Priya Parmar; Rita Krishnamurthi; Suzanne Barker-Collo; Valery Feigin; Yannick Bejot; Norberto Luiz Cabral; Antonio Carolei; Simona Sacco; Nicolas Chausson; Stephane Olindo; Peter Rothwell; Carolina Silva; Manuel Correia; Rui Magalhães; Peter Appelros; Janika Kõrv; Riina Vibo; Cesar Minelli; Seana L Gall
Journal:  Neurology       Date:  2018-04-27       Impact factor: 9.910

2.  Suppression of NDRG2 alleviates brain injury after intracerebral hemorrhage through mitigating astrocyte-drived glutamate neurotoxicity via NF-κB/GLT1 signaling.

Authors:  Jiahua Zhou; Kai Tao; Kang Guo; Lin Wu; Zhiguo Zhang; Dayun Feng; Guodong Gao; Huaizhou Qin
Journal:  Brain Res       Date:  2019-12-13       Impact factor: 3.252

Review 3.  Sex matters in stroke: A review of recent evidence on the differences between women and men.

Authors:  Cheryl Carcel; Mark Woodward; Xia Wang; Cheryl Bushnell; Else Charlotte Sandset
Journal:  Front Neuroendocrinol       Date:  2020-09-01       Impact factor: 8.606

Review 4.  Stroke in women: disparities and outcomes.

Authors:  Rebecca W Persky; Lisa Christine Turtzo; Louise D McCullough
Journal:  Curr Cardiol Rep       Date:  2010-01       Impact factor: 2.931

Review 5.  A critique of the Women's Health Initiative hormone therapy study.

Authors:  Edward L Klaiber; William Vogel; Susan Rako
Journal:  Fertil Steril       Date:  2005-12       Impact factor: 7.329

6.  Alleviation of ischaemia-reperfusion injury by endogenous estrogen involves maintaining Bcl-2 expression via the ERα signalling pathway.

Authors:  Zeng-Li Zhang; Pei Qin; Yuhong Liu; Li-Xia Zhang; Hang Guo; You-Liang Deng; Yu-Shu Hou; Li-Yang Wang; Yi Miao; Yu-Long Ma; Wu-Gang Hou
Journal:  Brain Res       Date:  2017-02-12       Impact factor: 3.252

Review 7.  Astrocyte-specific NDRG2 gene: functions in the brain and neurological diseases.

Authors:  Xin Li; Xiuquan Wu; Peng Luo; Lize Xiong
Journal:  Cell Mol Life Sci       Date:  2019-12-13       Impact factor: 9.261

8.  Selective activation of estrogen receptor β alleviates cerebral ischemia neuroinflammatory injury.

Authors:  Hang Guo; Jingrun Yang; Min Liu; Long Wang; Wugang Hou; Lixia Zhang; Yulong Ma
Journal:  Brain Res       Date:  2019-10-29       Impact factor: 3.252

9.  Estrogen replacement therapy-induced neuroprotection against brain ischemia-reperfusion injury involves the activation of astrocytes via estrogen receptor β.

Authors:  Yulong Ma; Hang Guo; Lixia Zhang; Liang Tao; Anqi Yin; Zhaoyu Liu; Yan Li; Hailong Dong; Lize Xiong; Wugang Hou
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

10.  Sex Differences in Severity of Stroke in the INSTRUCT Study: a Meta-Analysis of Individual Participant Data.

Authors:  Hoang T Phan; Mathew J Reeves; Christopher L Blizzard; Amanda G Thrift; Dominique A Cadilhac; Jonathan Sturm; Petr Otahal; Peter Rothwell; Yannick Bejot; Norberto L Cabral; Peter Appelros; Janika Kõrv; Riina Vibo; Cesar Minelli; Seana L Gall
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.